Psychedelic Headlines | May 20th

May 20, 2022
Headlines

Helping investors discover, understand, and stay up-to-date on investment opportunities within the Psychedelic industry.


Markets

Performance of psychedelic public companies this past week.


Company News

Numinus Wellness ($NUMI | $NUMIF) received Health Canada Special Access Program approval to provide psilocybin-assisted therapy to a patient with treatment-resistant depression. This is Numinus' first psilocybin-assisted therapy treatment outside of ongoing clinical trials. Press Release

MindMed ($MMED | $MNMD) provided positive safety and tolerability results from their Phase I trial focused on their non-hallucinogenic proprietary ibogaine analogue as a potential treatment for opioid withdrawal. Press Release

PsyBio Therapeutics ($PSYB | $PSYBF) achieved a commercially scalable purification method for one of their second generation compounds. The manufacturing process is expected to further expand PsyBio's portfolio of compounds that can be more readily and rapidly developed than competitive methods. Press Release

Awakn Life Sciences ($AWKN | $AWKNF) completed the world's first ketamine treatment study for behavioral addictions, including gambling disorder, internet gaming disorder, binge eating disorder and compulsive sexual behavior. Press Release

HAVN Life ($HAVN | $HAVLF) partnered with TheraPsil and will participate in their Project Solace as a Health Canada-approved licensed dealer to supply GMP-quality psilocybin for legal and therapeutic use via the Special Access Program. Press Release

Filament Health ($FH | $FLHLF) has been issued a second patent for the extraction and standardization of natural psilocybin. The patent describes technology for transforming variable psychedelic raw materials into pharmaceutical-grade drug candidates. Press Release

Optimi Health ($OPTI | $OPTHF) acquired a diverse catalog of psilocybin and functional mushroom strains used for cultivation in their, EU-GMP compliant facility in British Columbia. The acquisition includes 24 psychedelic and nine functional strains, giving it one of the largest genetic banks in the sector. Press Release

Clearmind Medicine ($CMND | $CMNDF) announced positive results from their proprietary psychedelic molecule, MEAI, as a potential treatment for alcohol addiction. Pre-clinical trial demonstrated safety and efficacy in reducing alcohol consumption. Press Release

Braxia Scientific ($BRAX | $BRAXF) received Health Canada Special Access Program approval to provide psilocybin-assisted psychotherapy for an Ontario patient with Major Depressive Disorder through their wholly owned subsidiary Canadian Rapid Treatment Centre of Excellence. Press Release

Albert Labs International ($ABRT) has been granted a Health Canada License for their research and production facility. This approval allows the legal possession, production, assembly, sale, and delivery of psilocybin and other psychoactive controlled substances. Press Release


Media

Psychedelic Finance: Interview With Aaron Bartlone Of Cybin

BNN Bloomberg: Investors Are Talking About Psychedelics

ABC: Australia's CSIRO Looks At Psychedelics And Mental Health

Global News: First Patient In Quebec Gets Approval From Health Canada for Psychedelic Therapy

Forbes: Psychedelics As Treatment Options For Mental Health


Be the first to see new company features, exclusive interviews and breaking news in the psychedelic markets. Subscribe now.

Always do your own research and make your own investment decisions. This is not a solicitation to purchase or sell securities. Psychedelic Finance is not a registered investment advisor and does not purport to provide investment advice, whether implied or otherwise. Psychedelic Finance does not independently verify the accuracy or the truth of the statements or representations made by issuers. This message is meant for information and educational purposes only and Psychedelic Finance does not intend for this information to be used to inform an investment decision.